Please read the About page for important background information on this site.

Blausen_0704_ParkinsonsDisease 580px-3,4-Dihydroxy-L-phenylalanin_(Levodopa).svg

The physiological basis of Parkinson’s (including known causes)

Current and future therapeutics for Parkinson’s

Recent drug approvals for Parkinson’s disease:

  • 2017:  Safinamide (Xadago), for symptomatic benefit
  • 2016:  Pimavanserin (Nuplazid), for hallucinations and delusions associated with Parkinson’s disease psychosis
  • 2015:  Rytary, a new extended-release formulation of levodopa/carbidopa (the same drugs in Sinemet), discussed briefly on the levodopa pharmacokinetics page
  • 2015:  Duopa, levodopa/carbidopa delivered directly into the small intestine, to reduce off time and dyskinesias, also discussed briefly on the levodopa pharmacokinetics page
  • 2014:  Droxidopa (Northera), for orthostatic hypotension (low blood pressure, especially upon standing up)